Sign In
Buy VATE
$8.12
+0 (+0%)
At Close: Jul 31, 2026
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced that R2 Technologies, Inc. (“R2”), the innovators behind the breakthr
INNOVATE Corp. (VATE) Q2 2025 Earnings Call Transcript
07:22pm, Tuesday, 05'th Aug 2025
INNOVATE Corp. (NYSE:VATE ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Michael J. Sena - CFO, Treasurer & Corporate Secretary Neel Sikka - Corporate Participant Pa
INNOVATE Corp. Announces Second Quarter 2025 Results
04:05pm, Tuesday, 05'th Aug 2025
- Infrastructure: Improved financial flexibility with recent refinancing transactions - - Life Sciences: R2 continuing to see significant year over year growth in system unit sales - - Spectrum: Launc
INNOVATE Closes Indebtedness Refinancing Transactions
04:30pm, Monday, 04'th Aug 2025
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced that it has closed a series of previously announced indebtedness refinanci
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced the early participation results as of 5:00 p.m., New York City time, on Ju
INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend
04:15pm, Monday, 28'th Jul 2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully i
INNOVATE Corp. to Report Second Quarter 2025 Results on August 5th
04:05pm, Thursday, 17'th Jul 2025
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the second quarter 2025 on
INNOVATE Launches Indebtedness Refinancing Transactions
08:42am, Thursday, 17'th Jul 2025
$48.7 million privately negotiated convertible notes exchanges.$330 million exchange offer of senior secured notes and solicitation of consentsAgreement in principle to extend revolving credit agreeme
INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend
04:12pm, Friday, 23'rd May 2025
NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully in
DBM Global Enters Into an Amended and Restated Credit Agreement
04:06pm, Tuesday, 20'th May 2025
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), has entered into an amended and restated
INNOVATE Corp. (VATE) Q1 2025 Earnings Call Transcript
09:02pm, Tuesday, 06'th May 2025
INNOVATE Corp. (NYSE:VATE ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Anthony Rozmus - Investor Relations Paul Voigt - Interim Chief Executive Officer Mike Sena - Ch
INNOVATE Corp. Announces First Quarter 2025 Results
04:05pm, Tuesday, 06'th May 2025
- Infrastructure: DBM Global first quarter revenue of $264.9 million - - Life Sciences: MediBeacon ® Transdermal GFR (“TGFR”) System Received FDA Approval to Assess Kidney Function - - Spectrum:
INNOVATE Corp. to Report First Quarter 2025 Results on May 6th
04:05pm, Wednesday, 16'th Apr 2025
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the first quarter 2025 on
INNOVATE Corp. (VATE) Q4 2024 Earnings Call Transcript
10:46pm, Monday, 31'st Mar 2025
INNOVATE Corp. (NYSE:VATE ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Neel Sikka - Investor Relations Paul Voigt - Interim Chief Executive Officer Mike Sena - Chi
INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results
04:04pm, Monday, 31'st Mar 2025
- Infrastructure: DBM Global fourth quarter revenue of $225.7 million - - Life Sciences: MediBeacon ® Transdermal GFR (“TGFR”) system received FDA approval to assess kidney function - - Spectrum:
